LivaNova’s Essenz perfusion system launches in China

LONDON - LivaNova PLC (NASDAQ:LIVN), a medical technology company with a market capitalization of $2.93 billion, announced Monday the commercial launch of its Essenz Perfusion System in China following approval from the country’s National Medical Products Administration. China represents LivaNova’s second-largest market for heart-lung machines after the United States. The company’s stock has shown strong momentum, gaining over 8% in the past week and trading near its 52-week high.

The Essenz system, designed for cardiopulmonary bypass procedures, has supported over 100,000 patients worldwide since its initial launch in February 2023, according to a company press release.

China’s cardiac surgery market presents significant potential, with approximately 330 million individuals affected by cardiovascular disease in the country. About 700 hospitals in China currently perform cardiac surgery, with projections indicating approximately 185,000 adult and 23,500 pediatric extracorporeal circulation procedures will be performed there in 2025. According to InvestingPro data, LivaNova’s revenue has grown 8.23% over the last twelve months, with analysts expecting continued growth this year. For deeper insights into LivaNova’s growth prospects and 11 additional ProTips, consider exploring InvestingPro’s comprehensive analysis.

The system includes the Essenz heart-lung machine, Patient Monitor, and In-Line Blood Monitor. Each component was developed in collaboration with more than 300 perfusionists globally to address evolving operating room needs, with emphasis on patient safety and risk management.

Stephen Robins, Chief Perfusionist at The Royal Wolverhampton NHS Trust in the United Kingdom, who participated in the system’s design, conducted an academic session during launch events in China. He noted the technology "gives the perfusionist and surgeon enhanced ergonomics, information, and control."

Besides China and the U.S., the Essenz Perfusion System is currently available in Europe, Canada, Australia, Japan, and the United Arab Emirates, among other markets.

Franco Poletti, LivaNova’s President of Cardiopulmonary, stated that introducing Essenz to the Chinese market "will provide perfusionists and surgeons with enhanced safety and control during life-saving procedures."

In other recent news, LivaNova has reported its second-quarter 2025 results, surpassing analyst expectations with robust performance across its business segments. The company achieved adjusted earnings per share of $1.05, well above the consensus estimate of $0.87. Revenue totaled $352.5 million, exceeding the anticipated $332.21 million and marking a 10.7% increase compared to the previous year. Notably, on an organic basis, revenue grew by 10.3%.

Goldman Sachs responded to these results by raising its price target for LivaNova to $168, maintaining a Buy rating. The investment bank highlighted strong performance in LivaNova’s Concerts segment and in-line results in Sponsorships & Ticketing. Additionally, Mizuho increased its price target for the company to $65, citing an Outperform rating. Mizuho attributed the strong quarterly performance to a $20 million revenue beat and earnings surpassing expectations by $0.18 per share, driven by momentum in the Cardiopulmonary segment and the Essenz HLM launch in Europe.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.